Global Medical REIT price target lowered to $11.25 from $12.50 at Compass Point

Compass Point analyst Merrill Ross lowered the firm’s price target on Global Medical REIT to $11.25 from $12.50 and keeps a Buy rating on the shares after the company reported Q3 results that were in line with the firm’s estimate. While stating that a strategy of recycling capital during a period of interest rate volatility “involves a significant degree of execution risk,” the firm has confidence in Global Medical’s management team, the analyst tells investors.